Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505413 | 0.80 | IRAK4 (0.43) | PDE2AKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL23728472 | 0.79 | ALDH1A1 (0.55) | HSD11B1PDE2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL310126 | 0.79 | PDE2A (0.59) | HSD11B1PDE2AKDM4EALDH1A1TDP1 | |
| SCHEMBL309283 | 0.79 | KDM4E (0.43) | PDE2AKDM4EALDH1A1TDP1IRAK4 | |
| SCHEMBL310187 | 0.79 | KDM4E (0.43) | PDE2AKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL28667748 | 0.79 | KDM4E (0.41) | HSD11B1PDE2AKDM4EALDH1A1TDP1 | |
| SCHEMBL308924 | 0.77 | KDM4E (0.42) | PDE2AKDM4EALDH1A1TDP1IRAK4 | |
| SCHEMBL12505460 | 0.76 | IRAK4 (0.43) | HSD11B1PDE2AKDM4EALDH1A1TDP1 | |
| SCHEMBL357371 | 0.76 | KDM4E (0.40) | PDE2AKDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL357836 | 0.76 | LMNA (0.45) | PDE2AKDM4EALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230099344-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2313413-B1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | CONVERGENCE PHARMACEUTICALS (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2313413-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2011-04-27 | — | — | EP | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | HSD11B1 4779/4885PDE2A 660/4885KDM4E 3426/4885 |
| US-20230099344-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | IRAK1, IRAK4, IRAK2 | HSD11B1 1889/4885PDE2A 4478/4885KDM4E 441/4885 |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885PDE2A 3378/4885KDM4E 190/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | HSD11B1 3076/4885PDE2A 2124/4885KDM4E 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.